Millipede, Inc. Announces Successful Clinical Use of the First Adjustable, Retrievable Transcatheter Complete Mitral Annuloplasty Ring

Friday, May 12, 2017 Clinical Trials News
Email Print This Page Comment bookmark
Font : A-A+

Transcatheter Procedures Mark Important Milestone in Clinical Program and Expanding Access for Patients

SANTA ROSA, Calif., May 12, 2017 /PRNewswire/ -- Millipede, Inc., an innovator in the field of transcatheter mitral and

tricuspid valve repair, announced today that it has successfully completed its first clinical use of its transcatheter IRIS Complete Annuloplasty Ring.  Two patients suffering from clinically significant mitral valve regurgitation and heart failure were successfully treated using the catheter-based system.  Both patients were discharged from the hospital within 48 hours of the procedure.

These first transcatheter procedures were performed at the Italian Hospital in Asuncion, Paraguay by Dr. Jason Rogers, Professor of Cardiovascular Medicine, UC Davis and Professor Eberhard Grube, Head, Center of Innovative Innovations, Heart Center Bonn, University Bonn, Germany with Steven F. Bolling, Professor of Cardiac Surgery, University of Michigan, in attendance. "The successful percutaneous implant of the IRIS Complete Annuloplasty Ring represents a breakthrough in the transcatheter treatment of functional and possibly degenerative mitral insufficiency," said Professor Eberhard Grube.

"The ability to deliver the gold standard for mitral valve repair -- a complete annuloplasty ring -- via a transfemoral venous approach has the potential to expand options for patients around the world," said Jason Rogers. "We are extremely pleased with the early outcomes of these first transcatheter cases."

"These cases are an important milestone in our on-going clinical experience and builds on the successful mitral and tricuspid implants previously completed by the team," said Randy Lashinski, CEO of Millipede.

The Millipede IRIS Transcatheter Annuloplasty Ring is a complete semi-rigid annuloplasty ring reproducing the current surgical standard of care for valvular regurgitation.  Placed in the supra-annular position, the implant avoids any impact to the left-ventricular outflow tract.  The transcatheter implant is repositionable and adjustable, optimizing annular reduction under echocardiography. The IRIS Complete Annuloplasty Ring also enables future repair or valve replacement thus preserving options for the patient and physician.

About Millipede, Inc.

Millipede, Inc. (www.millipedemedical.com) is based in Santa Rosa, California with the goal of providing catheter delivery of the gold standard in heart valve repair – a complete annuloplasty ring.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/millipede-inc-announces-successful-clinical-use-of-the-first-adjustable-retrievable-transcatheter-complete-mitral-annuloplasty-ring-300456710.html

SOURCE Millipede, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook